Incidence and outcome of chronic rejection in CyA- and FK 506-treated patients.
Platz
K P
KP
Department of Surgery, Virchow Clinic, Humboldt University Berlin, Germany.
Tullius
S G
SG
Mueller
A R
AR
Schumacher
G
G
Nüssler
N
N
Neuhaus
R
R
Bechstein
W O
WO
Lobeck
H
H
Neuhaus
P
P
D000961:Antilymphocyte Serum / Q000627:therapeutic use; D002908:Chronic Disease; D016572:Cyclosporine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000188:drug therapy / Q000453:epidemiology* / Q000401:mortality; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015994:Incidence; D016031:Liver Transplantation / Q000276:immunology* / Q000401:mortality; D012086:Reoperation; D012189:Retrospective Studies; D015996:Survival Rate; D016559:Tacrolimus / Q000627:therapeutic use*; D016896:Treatment Outcome
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D016559:Tacrolimus